Drugs.com - Pharma Industry News

Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer

WEDNESDAY, Feb. 19, 2025 -- For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall...

Feb 19, 2025 - 18:52
 0
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
WEDNESDAY, Feb. 19, 2025 -- For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall...
Read More

Tags:

Previous Article

Depression Tied to Having More Physical Health Conditions

Next Article

Calls to Poison Centers on the Rise for Pediatric Exposures to Caffeine Energy P...

Related Posts

Globally, 25.2 Million Projected to Be Living With Parkinson Disease in 2050

Globally, 25.2 Million Projected to Be Living With Park...

Mar 10, 2025  0

Risk for Lymphoma, Skin Cancer Increased in Individuals With Tattoos

Risk for Lymphoma, Skin Cancer Increased in Individuals...

Mar 7, 2025  0

Study Reveals Link Between Forever Chemicals and Childhood Cancers

Study Reveals Link Between Forever Chemicals and Childh...

Mar 5, 2025  0